28611039 26615179 28661758 32412789 31479143 25824444 29618460 31072694 26552376 27479221 27607852 33882282 29243522 30824471 25802306 30580266 28912973 33489426 27351134 26371145 27987198 30145819 31494144 31636127 29785770 31898097 28735000 2988245 - Search Results

Year	Number of Results
2015	5
2016	5
2017	6
2018	5
2019	7
2020	5
2021	2
2022	0

1

Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Trivedi MS, et al. Cancer Prev Res (Phila). 2017 Aug;10(8):434-441. doi: 10.1158/1940-6207.CAPR-17-0100. Epub 2017 Jun 13. Cancer Prev Res (Phila). 2017. PMID: 28611039 Free PMC article.

2

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Land SR, et al. J Natl Cancer Inst. 2015 Nov 27;108(4):djv365. doi: 10.1093/jnci/djv365. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26615179 Free PMC article. Clinical Trial.

3

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).

Smith SG, Sestak I, Howell A, Forbes J, Cuzick J. Smith SG, et al. J Clin Oncol. 2017 Aug 10;35(23):2666-2673. doi: 10.1200/JCO.2016.71.7439. Epub 2017 Jun 29. J Clin Oncol. 2017. PMID: 28661758 Free PMC article. Clinical Trial.

4

High Expression of Asparagine Synthetase Is Associated with Poor Prognosis of Breast Cancer in Chinese Population.

Qin C, Yang X, Zhan Z. Qin C, et al. Cancer Biother Radiopharm. 2020 Oct;35(8):581-585. doi: 10.1089/cbr.2019.3295. Epub 2020 May 15. Cancer Biother Radiopharm. 2020. PMID: 32412789

5

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Nelson HD, et al. JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780. JAMA. 2019. PMID: 31479143

6

One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk.

Kerlikowske K, Gard CC, Sprague BL, Tice JA, Miglioretti DL; Breast Cancer Surveillance Consortium. Kerlikowske K, et al. Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):889-97. doi: 10.1158/1055-9965.EPI-15-0035. Epub 2015 Mar 30. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 25824444 Free PMC article.

7

A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ.

Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA, Bevers T. Brewster AM, et al. Cancer Prev Res (Phila). 2018 May;11(5):295-302. doi: 10.1158/1940-6207.CAPR-17-0314. Epub 2018 Apr 4. Cancer Prev Res (Phila). 2018. PMID: 29618460

8

Implementing a Population-Based Breast Cancer Risk Assessment Program.

Silver E, Wenger N, Xie Z, Elashoff D, Lee K, Madlensky L, Trent J, Petruse A, Johansen L, Naeim A. Silver E, et al. Clin Breast Cancer. 2019 Aug;19(4):246-253.e2. doi: 10.1016/j.clbc.2019.02.009. Epub 2019 Mar 11. Clin Breast Cancer. 2019. PMID: 31072694 Free article.

9

Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.

Karavites LC, Allu S, Khan SA, Kaiser K. Karavites LC, et al. BMC Cancer. 2015 Nov 9;15:878. doi: 10.1186/s12885-015-1893-6. BMC Cancer. 2015. PMID: 26552376 Free PMC article.

10

Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Burns RB, Schonberg MA, Tung NM, Libman H. Burns RB, et al. Ann Intern Med. 2016 Aug 2;165(3):194-204. doi: 10.7326/M16-0940. Ann Intern Med. 2016. PMID: 27479221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results